Halftone
Business

Judge Approves Bayer's Seven Billion Dollar Roundup Settlement

A Missouri judge has approved Bayer's seven point two five billion dollar settlement to resolve tens of thousands of claims that its Roundup weedkiller causes cancer. The ruling brings the company closer to containing a legal battle that has weighed on it for years.

AI-Synthesized2 min read
Judge Approves Bayer's Seven Billion Dollar Roundup Settlement
Balanced View — synthesized from 2 opposing sources

A Missouri state court judge on Friday approved Bayer's seven point two five billion dollar settlement of lawsuits alleging that its Roundup weedkiller causes cancer. Judge Timothy Boyer of the St. Louis circuit court found the agreement fair, reasonable and adequate. The settlement, announced in February, aims to resolve nearly all current and future Roundup claims in the United States.

Bayer faced approximately sixty five thousand claims in state and federal courts from people who said they developed cancer after using Roundup at home or on the job. The company bought Monsanto, the maker of Roundup, for sixty three billion dollars in twenty eighteen. Since then, Bayer's share price has fallen by forty six percent.

The settlement applies to Roundup users who are already ill and to those diagnosed with non-Hodgkin lymphoma in future years. Individual payouts could average between ten thousand and one hundred sixty five thousand dollars. The amount depends on how the product was used, the person's age at diagnosis and the severity of the illness. The deal includes six hundred million dollars for attorneys' fees.

Bayer denies that Roundup causes cancer. The company has said the settlement provides financial certainty against mounting litigation costs. Bayer has already changed the formula for its Roundup version sold to residential users. It has also considered pulling the product from United States agricultural markets. CEO Bill Anderson called the court's final approval a decisive milestone in the company's strategy to manage the risks of pending and future litigation.

Some attorneys for cancer patients argued that the payouts are too small, especially compared with earlier settlements. Judge Boyer overruled those objections. He said delaying payouts could force victims, including those with terminal cancer, to wait an indeterminate number of years. He also said there was a risk Bayer would have sought bankruptcy protection if the settlement had been rejected.

While the settlement was pending, the United States Supreme Court undercut one of the central arguments in the Roundup lawsuits. In June, the court ruled that Bayer cannot be sued in state courts on claims that it failed to warn about cancer. The reason is that federal regulations do not require a cancer warning label, and states are forbidden from imposing additional labeling requirements. Some attorneys argued the deal was better than getting nothing, a possibility they said became more likely after that ruling. The decision could still be appealed.

Synthesized by AI from the sources cited above. Learn how our pipeline works or report a factual correction.
Sponsored
Keep reading

Related stories